Zhong Guo Jing Ji Wang·2026-01-22 02:30Group 1 - The Beijing Stock Exchange's listing committee approved Changzhou Baijiji Bio-Medical Co., Ltd. for its initial public offering (IPO), marking it as the 10th company to pass the review in 2026, with 5 from the Shanghai and Shenzhen stock exchanges and 5 from the Beijing Stock Exchange [1][2] - Baijiji specializes in the research, production, and sales of biomedical materials, focusing on innovative development of tissue repair and regeneration materials [1][2] - The company plans to issue up to 9.2072 million shares, potentially increasing to 10.5883 million shares if the overallotment option is fully exercised, with a public shareholder ownership ratio of no less than 25% post-issuance [2] Group 2 - The funds raised, amounting to 105.931 million yuan, will be allocated for the construction of a biodegradable biomedical materials industrial base [2] - The review meeting raised inquiries regarding the sustainability of the company's performance growth, specifically asking for evidence on market size expectations and the progress of R&D and market development [2]